←
ProBio91 posts
ProBio avatar

ProBio

@ProBioTrial

ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer

◷ Joined January 2019▧ 51 Photos and videos
ProBio avatar
ProBio@ProBioTrial·May 20

📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.

Post attachment
ProBio avatar
ProBio@ProBioTrial·May 20

💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with: ✅ Longer time of clinical benefit (PCWG3) ✅ Longer overall survival ✅ Fewer (S)AE

Post attachment
ProBio avatar
ProBio@ProBioTrial·May 20

🎯By integrating liquid biopsy profiling, multi-arm platform methodology, patient-reported outcomes, and international collaboration, ProBio-mHSPC seeks to move from “one-size-fits-all” towards more precise, evidence-based care.

ProBio avatar
ProBio@ProBioTrial·May 20

🚨 What makes this trial novel?  🩸🧬ctDNA guidance ⬇️ De-escalation for patients with undetectable ctDNA, testing deferred ADT ⬆️ Biomarker-guided intensification for patients with detectable ctDNA to identify who benefits from docetaxel- or PARP-combinations

ProBio avatar
ProBio@ProBioTrial·22 Apr 2025

Why does this matter? 🧬 Patients with undetectable ctDNA may need less intensive treatment & monitoring. Towards a ctDNA-driven de-escalation strategy? ⚠️ Patients with high ctDNA in their🩸 may benefit from earlier aggressive treatment [6/8]

ProBio avatar
ProBio@ProBioTrial·22 Apr 2025

🏅Secondary result: We found a linear relationship between ctDNA 🩸 levels and outcome: 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome! #PrecisionMedicine [5/8]

Post attachment
ProBio avatar
ProBio@ProBioTrial·22 Apr 2025

🏅Key result: 🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had ➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB) ➡️a 51% longer overall survival (OS) 📉 #CancerBiomarkers [4/8]

Post attachment